NIH R01 · 2025
Metabolic control of malignant fates in lung cancer
PROJECT SUMMARY Lung adenocarcinoma (LUAD) is a significant public health burden in the United States, causing an estimated 55,000 deaths annually. Despite advances in immunotherapies, chemotherapies, and oncoprotein-targeted therapies, most patients ultimately relapse and cures remain elusive. Within a tumor, LUAD cancer cells adopt a spectrum of cell states endowed with variable potential for malignant progression and treatment resistance. Whether these different cell states have different metabolic preferences, and whether targeting these preferences can eliminate specific cell states, remains poorly understood. Using cell lines derived from mouse and human LUAD tumors, we discovered…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.